Clinical Trial Update: A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection [Phase 2]

View source ↗

Summary

Phase 2 single-arm pilot studying adjuvant pembrolizumab plus trastuzumab in HER2-positive esophagogastric tumors with persistent circulating tumor DNA after cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophagogastric Cancer
• Gastric Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophagogastric Tumors, Gastric Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-02-01